PsychU

Sorry, this content is no longer available.

Explore Other Content
Welcome to PsychU!
Improving mental health care...together

Schizophrenia Treatment Goals & Shared Decision Making: A Practice-Based Learning Webinar

On-Demand Webinar November 9, 2022
  1. Home
  2. I Am A Provider
  3. Schizophrenia Treatment Goals & Shared Decision Making: A Practice-Based Learning Webinar

Join Dr. Correll and Dr. Schooler for a discussion on how to engage patients in their own treatment decisions, help them define their treatment goals, and address treatment barriers that are often associated with schizophrenia. Together, they lead an engaging practice-based learning session designed to both teach shared decision-making strategies and then demonstrate how they put them into practice.

Featuring:

Christoph-Correll

Christoph Correll, MD

Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.

More
Professor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness. He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.
Nina R.-Schooler

Nina R. Schooler, PhD

Professor of Psychiatry and Behavioral Sciences; State University of New York Downstate Medical Center

More
Professor Schooler’s research focuses on treatment of psychosis and schizophrenia from its earliest identification to long-term course and outcomes. Her expertise spans both pharmacologic and psychosocial interventions. Other areas of research focus on tardive dyskinesia and the systematic assessments of side effects, assessment and treatment of negative symptoms and assessment of social and vocational function measures as key to understanding long-term outcomes for schizophrenia and psychosis. Most recently her work has turned to integrating measurement-based care into treatment programs for first episode psychosis.
Linzy-Hendrickson

Linzy Hendrickson, PhD (OPDC)

Senior Medical Science Liaison

Download Slidedeck

Christoph Correll, MD and Nina Schooler, PhD are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Linzy Hendrickson, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.

US.CORP.X.22.00614 / US.CORP.D.22.00058 / US.CORP.V.22.00059

Upcoming Events

View All Upcoming Events

On-Demand Webinars

View On-Demand Webinar Library

Stay Connected: